• September 1, 2020

    Emalex Biosciences Phase 2b Tourette Syndrome Clinical Trial Reaches Enrollment Milestone

    – Half of participants are now enrolled in [...]

  • August 21, 2020

    Harmony Biosciences Announces Closing of its Upsized Initial Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

    PLYMOUTH MEETING, PA and CHICAGO, IL, August 21, [...]

  • August 19, 2020

    Harmony Biosciences Announces Pricing Of Upsized Initial Public Offering

    PLYMOUTH MEETING, PA and CHICAGO, IL, August 18, [...]

  • August 12, 2020

    Paragon Biosciences Appoints Kerensa Jimenez as Paragon Health Capital Chief Executive Officer

    Chicago, August 12, 2020 – With strong momentum [...]

  • July 23, 2020

    Synthetic Protein Design and Production Publication Confirms Evozyne’s Revolutionary Technology

    Publication in peer-reviewed journal Science demonstrates the foundation [...]

  • June 3, 2020

    Horizon Technology Finance and Emalex Biosciences Announce $15 Million Venture Loan Facility

    – Biopharmaceutical company advancing clinical research evaluating novel [...]

  • May 19, 2020

    Philadelphia Magazine features a Paragon portfolio company as a leader in cell and gene therapy innovation

    May 19, 2020 – We are proud to share [...]

  • April 29, 2020

    Congratulations to Harmony Biosciences for being ranked 8th on the Fortune Best Healthcare and Biopharma workplaces list

    April 29, 2020 – Like all Paragon Biosciences companies, [...]